Biomedical (advanced)
Ended Definitive Contract Awarded Last action
- Contract number
- HHSN272200800056C
- Awardee
-
Janssen Vaccines & Prevention B.V. UEI VRE2EKNJTJJ4
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $69,856,436
Award facts
- Opportunity
-
- Advanced Development of Multivalent Filovirus (Ebola and Marburg) Hemorrhagic Fever Vaccines Award Notice · Posted Sep 4, 2007
- Contract value 81% obligated
-
- $69,856,435.90 Current, with exercised options
- $86,670,401.90 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 4 offers Basic Research
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Netherlands
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Funding Only Action | -$142,665 | |
| Funding Only Action | -$300,000 | |
| Funding Only Action | $611,627 | |
| Supplemental Agreement for work within scope | -$4,714,747 | |
| Other Administrative Action | -$365,509 | |
| Other Administrative Action | -$1,005,388 | |
| Other Administrative Action | -$349,840 | |
| Exercise an Option | $881,157 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Vendor DUNS or Name Change - Non-Novation | $0 | |
| Exercise an Option | $9,332,795 | |
| Supplemental Agreement for work within scope | $5,150,823 | |
| Other Administrative Action | -$1,408,083 | |
| Exercise an Option | $8,876,505 | |
| Exercise an Option | $7,385,046 | |
| Supplemental Agreement for work within scope | $1,669,700 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $1,783,358 | |
| Exercise an Option | $8,069,468 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Change Order | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $20,885,825 | |
| Other Administrative Action | $0 | |
| Original award | $13,496,364 |
Show all 31
About this award
This is a cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services. The contract, with a ceiling value of $86,670,401.90, is for biomedical (advanced) products and services. The prime contractor is Janssen Vaccines & Prevention B.V., a foreign-owned for-profit organization. The contract does not have a set-aside designation and has an ultimate completion date of September 30, 2023. This award may be part of a larger NIAID program focused on biomedical research and development to address infectious diseases.
Quick answers
Who was awarded contract HHSN272200800056C?
HHSN272200800056C was awarded to Janssen Vaccines & Prevention B.V. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 30, 2008.
How much is contract HHSN272200800056C worth?
The government has obligated $69,856,436 on HHSN272200800056C. Its potential value, with all options, is $86,670,402.
Was contract HHSN272200800056C competed?
The extent of competition for HHSN272200800056C was full and open competition. The government received 4 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award